Literature DB >> 7893590

Debrisoquine and mephenytoin oxidation in Sinhalese: a population study.

K Weerasuriya1, R L Jayakody, C A Smith, C R Wolf, G T Tucker, M S Lennard.   

Abstract

The frequency distributions of the 0-8 h urinary metabolic ratios of debrisoquine and mephenytoin were measured in 111 healthy, unrelated Sinhalese resident in Sri Lanka. Blood samples were taken from 77 of these subjects for CYP2D6 genotyping. Bimodality in the distribution of the log10 debrisoquine/4-hydroxydebrisoquine ratio was not evident from visual inspection and by kernel density analysis. The results of genotyping indicated that 82% of the population were either homozygous for the wild-type CYP2D6 gene or heterozygous for the wild type allele and the whole gene deletion. Eighteen per cent of the Sinhalese population were heterozygous for the CYP2D6B mutation and the wild-type allele. All of these genotypes give rise to the extensive metaboliser phenotype in white Caucasians. No CYP2D6A mutations were identified and no individuals who were homozygous for the mutant alleles were detected, which is in accord with an absence of phenotypic poor metabolisers of debrisoquine. The mutant CYP2D6 allele frequency in Sinhalese (9%) is only half that observed in white Caucasians. The S/R-mephenytoin ratio ranged from 0.09 to 2.27 (median 0.38). By visual inspection and kernel density analysis the distribution of the S/R-mephenytoin ratio was bimodal and, using a value of 0.9 for the antimode, 16 (14%) subjects were poor metabolisers. In conclusion, the prevalence of the poor metaboliser phenotype in Sinhalese appears much lower for debrisoquine and higher for mephenytoin than in white Caucasians. These findings are similar to those observed in Indians living in Bombay and in Oriental populations.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7893590      PMCID: PMC1364882          DOI: 10.1111/j.1365-2125.1994.tb04384.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  Frequency of impaired mephenytoin 4'-hydroxylation in an Indian population.

Authors:  B S Doshi; R D Kulkarni; B L Chauhan; G R Wilkinson
Journal:  Br J Clin Pharmacol       Date:  1990-11       Impact factor: 4.335

Review 2.  The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects.

Authors:  M Eichelbaum; A S Gross
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

3.  Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism--hypothesis testing.

Authors:  P R Jackson; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1989-12       Impact factor: 4.335

Review 4.  Genetic polymorphism of S-mephenytoin hydroxylation.

Authors:  G R Wilkinson; F P Guengerich; R A Branch
Journal:  Pharmacol Ther       Date:  1989       Impact factor: 12.310

5.  Blood genetic markers in Sri Lankan populations--reappraisal of the legend of Prince Vijaya.

Authors:  N Saha
Journal:  Am J Phys Anthropol       Date:  1988-06       Impact factor: 2.868

6.  Determination of acetylator phenotype in Sri Lankans.

Authors:  P L Perera; W M Weerasinghe
Journal:  Ceylon Med J       Date:  1987-03

7.  Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism.

Authors:  H Yokota; S Tamura; H Furuya; S Kimura; M Watanabe; I Kanazawa; I Kondo; F J Gonzalez
Journal:  Pharmacogenetics       Date:  1993-10

8.  Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection.

Authors:  M S Lennard; J H Silas; A J Smith; G T Tucker
Journal:  J Chromatogr       Date:  1977-03-11

9.  Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.

Authors:  J C McGourty; J H Silas; M S Lennard; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

10.  Reconstruction of human evolution: bringing together genetic, archaeological, and linguistic data.

Authors:  L L Cavalli-Sforza; A Piazza; P Menozzi; J Mountain
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

View more
  10 in total

1.  Genetic polymorphism of CYP2D6 in Tamil population.

Authors:  B K Abraham; C Adithan; J Mohanasundaram; C H Shashindran; K Koumaravelou; M Asad
Journal:  Eur J Clin Pharmacol       Date:  2001 Jan-Feb       Impact factor: 2.953

2.  Genetic polymorphism of CYP2D6 in a keralite (South India) population.

Authors:  B K Abraham; C Adithan; C H Shashindran; S Vasu; N A Alekutty
Journal:  Br J Clin Pharmacol       Date:  2000-03       Impact factor: 4.335

Review 3.  Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.

Authors:  I Fricke-Galindo; C Céspedes-Garro; F Rodrigues-Soares; M E G Naranjo; Á Delgado; F de Andrés; M López-López; E Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

4.  Genotype and allele frequency of CYP2D6 in Tamilian population.

Authors:  C Adithan; N Gerard; A T Naveen; K Koumaravelou; C H Shashindran; R Krishnamoorthy
Journal:  Eur J Clin Pharmacol       Date:  2003-08-27       Impact factor: 2.953

5.  Evidence for the polymorphic oxidation of debrisoquine and proguanil in a Khmer (Cambodian) population.

Authors:  S Wanwimolruk; M R Thou; D J Woods
Journal:  Br J Clin Pharmacol       Date:  1995-08       Impact factor: 4.335

Review 6.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 7.  Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19.

Authors:  D A Flockhart
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

8.  CYP2D6 polymorphisms may predict occurrence of adverse effects to tamoxifen: a preliminary retrospective study.

Authors:  Ishani Wickramage; Kamani Hemamala Tennekoon; Merenchi Arachchige Yasantha Ariyaratne; Asanka Sudeshini Hewage; Tharmini Sundralingam
Journal:  Breast Cancer (Dove Med Press)       Date:  2017-03-06

9.  Genetic variants in the cytochrome P450 2D6 gene in the Sri Lankan population.

Authors:  T D Praveen Tharanga; C M V Jinadasa; M F Risama; Priyadarshani Galappatthy; R L Jayakody; Vajira H W Dissanayake
Journal:  Indian J Hum Genet       Date:  2013-10

10.  Cytochrome P450 2D6 polymorphism in eastern Indian population.

Authors:  Monalisa Dhuya; Murari Mohan Pal; Avijit Hazra; Suparna Chatterjee; Nithya Gogtay
Journal:  Indian J Pharmacol       Date:  2020-08-04       Impact factor: 1.200

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.